BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18766003)

  • 21. The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma.
    Kwak YE; Jeon NK; Kim J; Lee EJ
    Ann N Y Acad Sci; 2007 Jan; 1095():99-112. PubMed ID: 17404023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
    J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
    Roy KR; Reddy GV; Maitreyi L; Agarwal S; Achari C; Vali S; Reddanna P
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):903-11. PubMed ID: 19685055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.
    Klenke FM; Gebhard MM; Ewerbeck V; Abdollahi A; Huber PE; Sckell A
    BMC Cancer; 2006 Jan; 6():9. PubMed ID: 16409625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
    Cervello M; Bachvarov D; Cusimano A; Sardina F; Azzolina A; Lampiasi N; Giannitrapani L; McCubrey JA; Montalto G
    OMICS; 2011 Jun; 15(6):383-92. PubMed ID: 21410330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
    Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
    Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells].
    Tang BD; Zhou Q; Lin QH; Liu SC
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1511-3. PubMed ID: 17959527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells.
    Nagahara T; Okano J; Murawaki Y
    Oncol Rep; 2007 Nov; 18(5):1281-90. PubMed ID: 17914586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase.
    Kim SH; Kim SH; Song YC; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():635-41. PubMed ID: 19723114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
    Basu GD; Liang WS; Stephan DA; Wegener LT; Conley CR; Pockaj BA; Mukherjee P
    Breast Cancer Res; 2006; 8(6):R69. PubMed ID: 17156488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects and mechanisms of silibinin on human hepatoma cell lines.
    Lah JJ; Cui W; Hu KQ
    World J Gastroenterol; 2007 Oct; 13(40):5299-305. PubMed ID: 17879397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
    Blumenthal RD; Waskewich C; Goldenberg DM; Lew W; Flefleh C; Burton J
    Clin Cancer Res; 2001 Oct; 7(10):3178-85. PubMed ID: 11595712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation.
    Yu L; Chen M; Li Z; Wen J; Fu J; Guo D; Jiang Y; Wu S; Cho CH; Liu S
    Mol Pharmacol; 2011 Mar; 79(3):608-17. PubMed ID: 21177414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer.
    Yoshinaka R; Shibata MA; Morimoto J; Tanigawa N; Otsuki Y
    Anticancer Res; 2006; 26(6B):4245-54. PubMed ID: 17201140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
    Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH
    Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer.
    Daikoku T; Tranguch S; Chakrabarty A; Wang D; Khabele D; Orsulic S; Morrow JD; Dubois RN; Dey SK
    Cancer Res; 2007 Jun; 67(11):5285-92. PubMed ID: 17545608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats.
    Paik YH; Kim JK; Lee JI; Kang SH; Kim DY; An SH; Lee SJ; Lee DK; Han KH; Chon CY; Lee SI; Lee KS; Brenner DA
    Gut; 2009 Nov; 58(11):1517-27. PubMed ID: 19201774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2.
    Maussang D; Langemeijer E; Fitzsimons CP; Stigter-van Walsum M; Dijkman R; Borg MK; Slinger E; Schreiber A; Michel D; Tensen CP; van Dongen GA; Leurs R; Smit MJ
    Cancer Res; 2009 Apr; 69(7):2861-9. PubMed ID: 19318580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells.
    Damdinsuren B; Nagano H; Wada H; Kondo M; Ota H; Nakamura M; Noda T; Natsag J; Yamamoto H; Doki Y; Umeshita K; Dono K; Nakamori S; Sakon M; Monden M
    Int J Oncol; 2007 Jan; 30(1):201-8. PubMed ID: 17143530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.